Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | UBE2N | P61088 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881064 | 0.96 | ALDH1A1 (0.62) | POLBMMP8MMP12MMP13UBE2N | |
| SCHEMBL7226664 | 0.93 | POLB (0.62) | POLBMMP8MMP12MMP13UBE2N | |
| SCHEMBL7226660 | 0.93 | POLB (0.62) | POLBMMP8MMP12MMP13UBE2N | |
| SCHEMBL12995467 | 0.82 | POLB (0.53) | POLBUBE2NALDH1A1RAB9A | |
| SCHEMBL1381814 | 0.82 | POLB (0.53) | POLBUBE2NALDH1A1RAB9A | |
| SCHEMBL23519421 | 0.77 | ALDH1A1 (0.65) | POLBMMP8MMP12MMP13ALDH1A1 | |
| SCHEMBL6996 | 0.77 | ALDH1A1 (0.65) | POLBMMP8MMP12MMP13ALDH1A1 | |
| SCHEMBL6997 | 0.77 | ALDH1A1 (0.65) | POLBMMP8MMP12MMP13ALDH1A1 | |
| SCHEMBL5282637 | 0.77 | MEN1 (0.72) | POLBALDH1A1RAB9A | |
| SCHEMBL6971945 | 0.77 | POLB (0.50) | POLBALDH1A1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | claimed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | claimed |
| US-9562043-B2 | Heterocyclic amide derivative and pharmaceutical product containing same | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562043-B2 | Heterocyclic amide derivative and pharmaceutical product containing same | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20150284375-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284375-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | TRPA1, TRPV1, TRPV2 | POLB 4765/4885MMP8 1141/4885MMP12 2543/4885 |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | TRPA1, TRPV1, TRPV2 | POLB 4839/4885MMP8 1988/4885MMP12 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.